Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1981 1
1983 2
1985 1
1986 2
1988 1
1989 1
2003 1
2004 2
2005 1
2007 1
2008 1
2013 2
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Unknown field was ignored: [3,2-d]
Page 1
Synthesis and In Silico Docking of New Pyrazolo[4,3-e]pyrido[1,2-a]pyrimidine-based Cytotoxic Agents.
Horchani M, Heise NV, Hoenke S, Csuk R, Harrath AH, Ben Jannet H, Romdhane A. Horchani M, et al. Int J Mol Sci. 2021 Sep 23;22(19):10258. doi: 10.3390/ijms221910258. Int J Mol Sci. 2021. PMID: 34638600 Free PMC article.
All compounds were evaluated for their in vitro cytotoxicity employing a panel of different human tumor cell lines, A375, HT29, MCF7, A2780, FaDu as well as non-malignant NIH 3T3 and HEK293 cells. It has been found that the pyrazolo-pyrido-pyrimidine analog bearing …
All compounds were evaluated for their in vitro cytotoxicity employing a panel of different human tumor cell lines, A375, HT29, MCF7, A2780, …
Biopharmaceutical profiling of a pyrido[4,3-d] pyrimidine compound library.
Wuyts B, Keemink J, De Jonghe S, Annaert P, Augustijns P. Wuyts B, et al. Int J Pharm. 2013 Oct 15;455(1-2):19-30. doi: 10.1016/j.ijpharm.2013.08.002. Epub 2013 Aug 7. Int J Pharm. 2013. PMID: 23933051
The pyrido-pyrimidine structure is associated with different biological activities, including kinase inhibition and antibacterial activity. ...
The pyrido-pyrimidine structure is associated with different biological activities, including kinase inhibition and antibacter …
Exploring the Antiproliferative Potency of Pyrido[2,3-d]Pyrimidine Derivatives: Studies on Design, Synthesis, Anticancer Evaluation, SAR, Docking, and DFT Calculations.
Abd-Alsalam E, Hafez HN, Assay MG, Ali AK, El-Farargy AF, Abbass EM. Abd-Alsalam E, et al. Chem Biodivers. 2024 Feb;21(2):e202301682. doi: 10.1002/cbdv.202301682. Epub 2024 Jan 11. Chem Biodivers. 2024. PMID: 38084395
Compound 1 was also submitted to react with different carbonyl compounds to afford pyrido-pyrimidine derivatives (12-15). All the newly synthesized compounds were tested in vitro for their antiproliferative activities against HCT-116 and MCF-7 cell lines. ...
Compound 1 was also submitted to react with different carbonyl compounds to afford pyrido-pyrimidine derivatives (12-15). All …
Synthesis of some new annulated pyrazolo-pyrido (or pyrano) pyrimidine, pyrazolopyridine and pyranopyrazole derivatives.
El-Assiery SA, Sayed GA, Fouda A. El-Assiery SA, et al. Acta Pharm. 2004 Jun;54(2):143-50. Acta Pharm. 2004. PMID: 15274757
Compound 2 was used as the key intermediate to prepare the pyrazolo-pyrido-pyrimidine derivatives through its reaction with formic acid, formamide-formic acid-DMF, ammonium thiocyanate or reaction with triethyl orthoformate followed by cyclization with hydrazine hyd …
Compound 2 was used as the key intermediate to prepare the pyrazolo-pyrido-pyrimidine derivatives through its reaction with fo …
4-quinolones inhibit biotransformation of caffeine.
Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. Harder S, et al. Eur J Clin Pharmacol. 1988;35(6):651-6. doi: 10.1007/BF00637602. Eur J Clin Pharmacol. 1988. PMID: 2853056 Clinical Trial.
The pharmacokinetics of caffeine, including formation of its major metabolite paraxanthine in plasma, has been investigated in 12 healthy males (age 20-40 years) alone and during co-administration of the 4-quinolones ofloxacin, norfloxacin, pipemidic acid, ciprofloxacin, and enox …
The pharmacokinetics of caffeine, including formation of its major metabolite paraxanthine in plasma, has been investigated in 12 healthy ma …
Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding.
Ballinger ML, Osman N, Wilks AF, Su S, Burns CJ, Bu X, Little PJ. Ballinger ML, et al. J Cardiovasc Pharmacol. 2008 Nov;52(5):403-12. doi: 10.1097/FJC.0b013e31818a8907. J Cardiovasc Pharmacol. 2008. PMID: 19033819
In human vascular smooth muscle cells (VSMCs), CYC10424 (Cytopia Research Ltd), a pyrido-pyrimidine derivative, dose-dependently decreased PDGF-mediated radiolabel incorporation into proteoglycans associated with an increase in electrophoretic mobility by SDS-PAGE. …
In human vascular smooth muscle cells (VSMCs), CYC10424 (Cytopia Research Ltd), a pyrido-pyrimidine derivative, dose-dependent …
Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives.
Basiri A, Murugaiyah V, Osman H, Kumar RS, Kia Y, Ali MA. Basiri A, et al. Bioorg Med Chem. 2013 Jun 1;21(11):3022-31. doi: 10.1016/j.bmc.2013.03.058. Epub 2013 Apr 1. Bioorg Med Chem. 2013. PMID: 23602518
A series of hitherto unreported pyrido-pyrimidine-2-ones/pyrimidine-2-thiones were synthesized under microwave assisted solvent free reaction conditions in excellent yields and evaluated in vitro for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) …
A series of hitherto unreported pyrido-pyrimidine-2-ones/pyrimidine-2-thiones were synthesized under microwave assisted solven …
In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects.
Guo XN, Zhong L, Tan JZ, Li J, Luo XM, Jiang HL, Nan FJ, Lin LP, Zhang XW, Ding J. Guo XN, et al. Cancer Biol Ther. 2005 Oct;4(10):1125-32. doi: 10.4161/cbt.4.10.2024. Epub 2005 Oct 15. Cancer Biol Ther. 2005. PMID: 16096368
Here, we aim to identify a novel potent tyrosine kinase inhibitor. Computer modeling of the pyrido-pyrimidine class compound, TKI-28(6-(2,6-dichlorophenyl)-8-methyl-2-phenylamino-8H-pyrido[2,3-d]pyrimidine-7-one), predicted that the compound would dock well in the A …
Here, we aim to identify a novel potent tyrosine kinase inhibitor. Computer modeling of the pyrido-pyrimidine class compound, …
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. von Bubnoff N, et al. Cancer Res. 2003 Oct 1;63(19):6395-404. Cancer Res. 2003. PMID: 14559829
We screened 13 different pyrido-pyrimidine with cells expressing wild-type and mutant BCR-ABL. ...This observation is consistent with the hypothesis that unlike imatinib, pyrido-pyrimidine inhibitors bind Bcr-Abl regardless of the conformation of the a …
We screened 13 different pyrido-pyrimidine with cells expressing wild-type and mutant BCR-ABL. ...This observation is consiste …
20 results